Transtympanic administration of short interfering (si)rna for the nox3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat

Antioxidants and Redox Signaling

Volumn 13, Issue 5, 2010, Pages 589-598

  Mukherjea, Debashree ^a   Jajoo, Sarvesh ^a   Kaur, Tejbeer ^a   Sheehan, Kelly E ^a   Ramkumar, Vickram ^a   Rybak, Leonard P ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; KIDNEY INJURY MOLECULE 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 3; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COCHLEA INJURY; CONTROLLED STUDY; EVOKED BRAIN STEM AUDITORY RESPONSE; HEARING LOSS; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NONHUMAN; OTOTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCANNING ELECTRON MICROSCOPY;

ANIMALS; APOPTOSIS; AUDITORY THRESHOLD; BCL-2-ASSOCIATED X PROTEIN; CELL ADHESION MOLECULES; CISPLATIN; COCHLEA; GENE EXPRESSION; HAIR CELLS, AUDITORY, OUTER; HEARING LOSS; MALE; NADPH OXIDASE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; TRPV CATION CHANNELS;

RATTUS;

EID: 77954935934     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2010.3110     Document Type: Article

References (38)

1. Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, and Bonventre JV. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 277: 39739-39748, 2002.
2. Banfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, and Krause KH. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 279: 46065-46072, 2004.
3. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, and Kanz L. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testic-ular cancer. Br J Cancer 77: 1355-1362, 1998.
4. Campbell KC, Meech RP, Rybak LP, and Hughes LF. D-Methionine protects against cisplatin damage to the stria vascularis. Hear Res 138: 13-28, 1999.
5. Choe WT, Chinosornvatana N, and Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 25: 910-915, 2004.
6. Fleischman RW, Stadnicki SW, Ethier MF, and Schaeppi U. Ototoxicity of cis-dichlorodiammine platinum (II) in the guinea pig. Toxicol Appl Pharmacol 33: 320-332, 1975.
7. Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gurur-angan S, Hassall T, Gronewold L, Stewart CF, Wallace D, Broniscer A, Hale GA, Kasow KA, Merchant TE, Morris B, Krasin M, Kun LE, Boyett JM, and Gajjar A. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 26: 3749-3755, 2008.
8. Hamid M and Trune D. Issues, indications, and controversies regarding transtympanic steroid perfusion. Curr Opin Otolaryngol Head Neck Surg 16: 434-440, 2008.
9. Herr BD and Marzo SJ. Transtympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 132: 527-531, 2005.
10. Hsieh LC, Lin HC, Tsai HT, Ko YC, Shu MT, and Lin LH. High-dose transtympanic gentamicin instillations for treatment of Meniere's disease: Long-term results. Acta Otolar-yngol 129: 1420-1424, 2009.
11. Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, Carpenter LS, Mai WY, Chintagumpala MM, South M, Grant WH, 3rd, Butler EB, and Woo SY. Intensity-modulated radiation therapy for pediatric medulloblastoma: Early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52: 599-605, 2002.
12. Hyppolito MA, de Oliveira AA, Lessa RM, and Rossato M. [Amifostine otoprotection to cisplatin ototoxicity: A guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy]. Braz J Otorhi-nolaryngol 71: 268-273, 2005.
13. Ichimura T, Hung CC, Yang SA, Stevens JL, and Bonventre JV. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 286: F552-563, 2004.
14. Kamimura T, Whitworth CA, and Rybak LP. Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. Hear Res 131: 117-127, 1999.
15. Kilic R, Safak MA, Oguz H, Kargin S, Demirci M, Samim E, and Ozluoglu LN. Transtympanic methylprednisolone for sudden sensorineural hearing loss. Otol Neurotol 28: 312-316, 2007.
16. Kopelman J, Budnick AS, Sessions RB, Kramer MB, and Wong GY. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 98: 858-864, 1988.
17. Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, Garcia P, Steinman H, Malgrange B, Ruben RJ, Rybak L, and Van de Water TR. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 18: 559-571, 1997.
18. Korver KD, Rybak LP, Whitworth C, and Campbell KM. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 126: 683-689, 2002.
19. Li Y, Womer RB, and Silber JH. Predicting cisplatin ototox-icity in children: The influence of age and the cumulative dose. Eur J Cancer 40: 2445-2451, 2004.
20. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 13: 228-244, 1995.
21. Mukherjea D, Jajoo S, Whitworth C, Bunch JR, Turner JG, Rybak LP, and Ramkumar V. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J Neurosci 28: 13056-13065, 2008.
22. Mukherjea D, Whitworth CA, Nandish S, Dunaway GA, Rybak LP, and Ramkumar V. Expression of the kidney injury molecule 1 in the rat cochlea and induction by cisplatin. Neuroscience 139: 733-740, 2006.
23. Nguyen KD, Minor LB, Della Santina CC, and Carey JP. Time course of repeated transtympanic gentamicin for Me-niere's disease. Laryngoscope 119: 792-798, 2009.
24. Ramkumar V, Whitworth CA, Pingle SC, Hughes LF, and Rybak LP. Noise induces A1 adenosine receptor expression in the chinchilla cochlea. Hear Res 188: 47-56, 2004.
25. Rybak LP. Cis-platinum associated hearing loss. J Laryngol Otol 95: 745-747, 1981.
26. Rybak LP, Husain K, Whitworth C, and Somani SM. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: Antioxidant defense system. Toxicol Sci 47: 195-202, 1999.
27. Rybak LP and Somani S. Ototoxicity. Amelioration by protective agents. Ann NY Acad Sci 884: 143-151, 1999.
28. Rybak LP, Whitworth C, and Somani S. Application of an-tioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 109: 1740-1744, 1999.
29. Rybak LP, Whitworth CA, Mukherjea D, and Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226: 157-167, 2007.
30. Sluyter S, Klis SF, de Groot JC, and Smoorenburg GF. Alterations in the stria vascularis in relation to cisplatin oto-toxicity and recovery. Hear Res 185: 49-56, 2003.
31. Soong R, Beyser K, Basten O, Kalbe A, Rueschoff J, and Tabiti K. Quantitative reverse transcription-polymerase chain reaction detection of cytokeratin 20 in noncolorectal lymph nodes. Clin Cancer Res 7: 3423-3429, 2001.
32. Stadnicki SW, Fleischman RW, Schaeppi U, and Merriam P. Cis-dichlorodiammineplatinum (II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys. Cancer Che-mother Rep 59: 467-480, 1975.
33. Staecker H, Liu W, Malgrange B, Lefebvre PP, and Van De Water TR. Vector-mediated delivery of bcl-2 prevents degeneration of auditory hair cells and neurons after injury. ORL J Otorhinolaryngol Relat Spec 69: 43-50, 2007.
34. Swan EE, Mescher MJ, Sewell WF, Tao SL, and Borenstein JT. Inner ear drug delivery for auditory applications. Adv Drug Deliv Rev 60: 1583-1599, 2008.
35. Tanaka F, Whitworth CA, and Rybak LP. Influence of pH on the ototoxicity of cisplatin: A round window application study. Hear Res 177: 21-31, 2003.
36. Thomas Dickey D, Muldoon LL, Kraemer DF, and Neuwelt EA. Protection against cisplatin-induced ototoxic-ity by N-acetylcysteine in a rat model. Hear Res 193: 25-30, 2004.
37. Van Wijk F, Staecker H, Keithley E, and Lefebvre PP. Local perfusion of the tumor necrosis factor alpha blocker in-fliximab to the inner ear improves autoimmune neurosen-sory hearing loss. Audiol Neurootol 11: 357-365, 2006.
38. Xenellis J, Papadimitriou N, Nikolopoulos T, Maragoudakis P, Segas J, Tzagaroulakis A, and Ferekidis E. Transtympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngol Head Neck Surg 134: 940-945, 2006.